Cardiff Oncology, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Cardiff Oncology reported positive Phase 2 CRDF-004 data (72.2% ORR vs. 42.1% for standard-of-care; PFS HR 0.55) supporting advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into Phase 3 for first-line RAS-mutated mCRC. Following successful FDA End-of-Phase 2 meeting, the company plans Phase 3 initiation in Q1 2027, contingent on securing additional financing. Cardiff completed a $10 million registered direct offering in July 2026 and reported $34.5M in cash as of June 30, 2026, with runway extending into Q3 2027. The company faces a material licensing dispute with Nerviano Medical Sciences (alleged breach, purported termination in February 2026; Cardiff filed lawsuit in May 2026 contesting the termination).
Why this rating
Phase 3 advancement with FDA alignment is strategically significant for a ~$205M biotech; $10M financing extends runway but depends on Phase 3 success. Licensing dispute is a material risk but currently contested. Event is meaningful relative to company size.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.